Shaanxi Meibang Pharmaceutical Group Co., Ltd. Class A

Shaanxi Meibang Pharmaceutical Group Co., Ltd. Class A

SSSE:605033
16.47
CNY
-0.28
(-1.67%)
0.47EPS
41.28P/E
2.65BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.69
4.66
5.21
5.63
7.64
6.68
5.22
6.49
6.75
7.39
Basic EPS, GAAP
0.68
0.63
0.77
0.78
1.14
1.07
0.43
0.27
0.36
0.47
Free Cash Flow per Basic Share
0.13
-0.19
0.96
0.13
-1.95
0.13
0.98
0.89
0.33
- -
Dividend per Share
0.04
0.04
0.02
0.01
0.03
0.2
0.22
0.21
0.18
0.18
Book Value per Share
1.83
2.81
3.66
4.43
7.15
7.88
8.24
8.32
8.53
8.81
Tangible Book Value per Share
1.76
2.72
3.57
4.35
7.1
7.79
7.63
7.44
7.66
7.97
Basic Weighted Avg Shares
90
94
99
101
110
136
134
137
135
136
Sales/Revenue/Turnover
422
439
516
569
842
906
699
886
912
1,003
Operating Margin (%)
18.67
18.47
19.2
16.1
16.5
16.61
8.57
4.19
7.1
11.01
Depreciation Expense
6
8
10
10
12
15
21
22
33
- -
Net Income, GAAP
61
59
76
79
126
145
58
37
49
64
Effective Tax Rate (%)
12.46
11.99
10.82
11.92
9.43
4.78
7.78
2.64
7.08
20.7
Profit Margin (%)
14.51
13.53
14.79
13.85
14.93
16.01
8.23
4.16
5.34
6.42
Working Capital
107
187
261
295
756
819
611
480
452
566
LT Debt
- -
- -
- -
- -
- -
- -
- -
72
136
147
Total Equity
180
276
371
449
967
1,086
1,114
1,125
1,153
1,191
Return on Invested Capital (%)
- -
21.77
21.36
17.87
15.35
12.87
4.24
2.58
3.84
- -
Return on Capital (%)
- -
23.71
22.1
18.48
17.84
14.04
5.26
3.19
3.92
- -
Return on Common Equity (%)
- -
25.98
23.57
19.2
17.76
14.13
5.23
3.29
4.27
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
11
11
1
LT Borrowings
147
147
147
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
3,085
2,250
2,650

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,077
954
1,025
Cash, Cash Equivalents & STI
583
376
529
Accounts Receivable, Net
205
271
142
Inventories
165
161
196
Total Current Liabilities
451
342
459
Payables & Accruals
- -
- -
- -
ST Debt
11
11
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.71%
2.52%
Free Cash Flow
- -
-249.53%
-63.21%
Net Income, GAAP
- -
2.17%
32.03%
Sales/Revenue/Turnover
- -
12.51%
2.98%
Total Cash Common Dividend
- -
214.56%
-14.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
312
198
113
263
886
2025
289
196
- -
303
912
2026
336
219
145
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.02
-0.03
-0.05
0.27
2025
0.22
0.05
- -
0.09
0.36
2026
0.26
0.11
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
0.06
0.21
2025
- -
- -
- -
0.08
0.18
2026
- -
0.1
- -
- -
- -

Company Description

CEO
Tong Zhang
Full Time Employees
1,117
Sector
Process industries
Industry
Chemicals: agricultural
Address
Shiyang Industrial Park Xi'an SA China 710018
IPO Date
Sep 16, 2021
Website
meibang.cn
Business
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS) engages in the research, development, production and sale of pesticide preparations, primarily serving the agricultural sector in China. The company offers a range of fungicides, including 80% dimethylmorpholine water dispersible granules, 27% chunleimycin bromonitrile wettable powder, 72% pyrazole ether ester combined water dispersible granules and 22% chunleimycin chlorobromoisocyanuric acid wettable powder; insecticides, such as 21% abamectin benzoate fenitrile suspension, 22% thiamethoxam beta cypermethrin suspension, 45% biphenyl hydrazide ethiconazole suspension and 20% fenitrile bifenthrin suspension; as well as herbicides, plant growth regulators, fertilizers and microbial fertilizers. Founded in 1998 and headquartered in the High-Tech Industrial Development Zone, Pucheng County, Weinan City, Shaanxi Province, China, the company operates principally within the domestic market with approximately 998 employees. In recent developments, Shaanxi Meibang Pharmaceutical Group invests CNY 50 million in Shaanxi Nuozheng Biotechnology Co., Ltd. to support strategic expansion in biotechnology; reports 2024 revenue of CNY 885.53 million, up 26.68% year-over-year despite a 35.96% decline in net income to CNY 36.86 million; and anticipates first-half 2025 results alongside ongoing compliance with national pesticide registration policies amid stable operations.